Real‐world eligibility for vericiguat in decompensated heart failure with reduced ejection fraction

Real‐world eligibility for vericiguat in decompensated heart failure with reduced ejection fraction

Abstract Aims In 2021, vericiguat was approved by the US Food and Drug Administration (FDA) and the European Commission (EC) for reducing cardiovascular mortality and heart failure (HF) hospitalizations in patients with HF with reduced ejection fraction (HFrEF) based on the Vericiguat Global Study i...

Full description

Bibliographic Details
Main Authors: Jaewon Oh, Chan Joo Lee, Jin Joo Park, Sang Eun Lee, Min‐Seok Kim, Hyun‐Jai Cho, Jin‐Oh Choi, Hae‐Young Lee, Kyung‐Kuk Hwang, Kye Hun Kim, Byung‐Su Yoo, Dong‐Ju Choi, Sang Hong Baek, Eun‐Seok Jeon, Jae‐Joong Kim, Myeong‐Chan Cho, Shung Chull Chae, Byung‐Hee Oh, Seok‐Min Kang
Format: Article
Language:English
Published: Wiley 2022-04-01
Series:ESC Heart Failure
Subjects:
Vericiguat
Heart failure
Eligibility
Clinical pharmacology
Registries
Online Access:https://doi.org/10.1002/ehf2.13837

Internet

https://doi.org/10.1002/ehf2.13837

Similar Items